Atomoxetine hydrochloride

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All pediatric patients 6 years of age or older treated with atomoxetine oral solution should be monitored and observed closely for suicidal thoughts and behaviors, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Consider stopping atomoxetine oral solution in patients who experience emergent suicidal thoughts and behavior [see Warnings and Precautions (5.1) ] . Atomoxetine increased the risk of suicidal ideation in pediatric patients 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies [see Warnings and Precautions (5.1) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER See full prescribing information for complete boxed warning. All pediatric patients 6 years of age and older treated with atomoxetine oral solution should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. ( 5.1 ) Consider stopping atomoxetine oral solution in patients who experience emergent suicidal thoughts and behavior. ( 5.1 ) Atomoxetine oral solution increased the risk of suicidal ideation in pediatric patients 6 years of age and older with attention deficit/ hyperactivity disorder (ADHD) in short-term studies. ( 5.1 )

5 WARNINGS AND PRECAUTIONS Severe Liver Injury: Atomoxetine oral solution should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury. ( 5.2 ) Serious Cardiovascular Reactions: Prior to atomoxetine oral solution treatment, patients should have a careful history and physical exam to assess for presence of cardiovascular (CV) disease. Atomoxetine oral solution generally should not be used in pediatric patients with known serious cardiac abnormalities, cardiomyopathy, serious arrhythmias. Consideration should be given to not using atomoxetine oral solution in adults with clinically significant cardiac abnormalities. Patients who develop symptoms suggestive of cardiac disease during atomoxetine oral solution treatment should stop atomoxetine oral solution and undergo a prompt cardiac evaluation. ( 5.3 ) Increase in Blood Pressure and Heart Rate: Heart rate and blood pressure should be measured at baseline, following atomoxetine oral solution dosage increases, and periodically while on therapy. ( 5.4 ) New Psychotic or Manic Symptoms and Activation of Mania: If psychotic or manic symptoms occur, consider discontinuing atomoxetine oral solution. ( 5.5 ) Aggressive Behavior or Hostility: Monitor for the appearance or worsening of aggressive behavior or hostility. ( 5.7 ) Effects on Urine Outflow: Urinary retention or hesitancy may occur. ( 5.8 ) Priapism: Prompt medical attention is required in the event of suspected priapism. ( 5.9 ) Effect on Growth in Pediatric Patients: Closely monitor growth (e.g., weight, height) in pediatric patients. ( 5.11 ) 5.1 Suicidal Thoughts and Behaviors in Pediatric Patients 6 Years of Age and Older All pediatric patients 6 years of age and older treated with atomoxetine oral solution should be monitored observed closely for clinical worsening, suicidal thoughts and behavior, and unusual changes in behavior, especially during the initial few months of atomoxetine oral solution therapy, or at times of dose changes, either increases or decreases. Families and caregivers of pediatric patients 6 years of age and older treated with atomoxetine oral solution should be alerted about the need to monitor patients daily for the emergence of agitation, irritability, unusual changes in behavior, and mental health-related symptoms, as well as the emergence of suicidal thoughts and behavior, and to report such symptoms immediately to a health care provider. Consider changing the therapeutic regimen, including stopping atomoxetine oral solution, in patients who experience emergent suicidality or symptoms that might be precursors to emerging suicidal thoughts and behavior, especially if these symptoms are severe or abrupt in onset, or were not part of the patient’s presenting symptoms. Atomoxetine increased the risk of suicidal ideation in pediatric patients 6 years of age and older with ADHD in pooled placebo-controlled short-term studies (6 to 18 weeks). In 12 studies (11 studies in patients with ADHD and 1 in another clinical study ) with over 2,200 pediatric patients, the mean incidence of suicidal ideation in pediatric patients treated with another atomoxetine product was 0.4% (5/1357) (including one patient with a suicide attempt) compared to 0% (0/851) in placebo-treated pediatric patients. No suicides occurred in these studies. All the suicidal ideations occurred in pediatric patients 6 to 12 years of age, and all occurred during the first month of treatment with the other atomoxetine product. It is unknown whether the risk of suicidal ideation in pediatric patients extends to longer-term use. A similar analysis in adult patients treated with atomoxetine for ADHD did not reveal an increased risk of suicidal ideation or behavior. The following psychiatric symptoms have been reported with the use of atomoxetine: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania and mania. Although a causal link between the emergence of such symptoms and the emergence of suicidal impulses has not been established, there is a concern that such symptoms may represent precursors to emerging suicidality. 5.2 Severe Liver Injury Atomoxetine oral solution should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury. Liver enzyme and function tests should be obtained upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu like” symptoms). Postmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6,000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use during postmarketing use. Rare cases of liver failure have been reported during postmarketing use, including a case that resulted in a liver transplant. Reported cases of liver injury occurred within 120 days of initiation of atomoxetine in most cases and some patients presented with markedly elevated liver enzymes (>20 times upper limit of normal (ULN)), and jaundice with significantly elevated bilirubin levels (>2 times ULN), followed by recovery upon atomoxetine discontinuation. In one patient, liver injury, manifested by elevated hepatic enzymes up to 40 times ULN and jaundice with bilirubin up to 12 times ULN, recurred upon rechallenge, and was followed by recovery upon atomoxetine discontinuation, providing evidence that atomoxetine likely caused the liver injury. Such reactions may occur several months after atomoxetine oral solution is started, but laboratory abnormalities may continue to worsen for several weeks after atomoxetine oral solution is stopped. 5.3 Serious Cardiovascular Reactions Risk Management Recommendations for Serious Cardiovascular Reactions Prior to atomoxetine oral solution treatment, adults or pediatric patients 6 years of age or older should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiovascular disease and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram, echocardiogram). Although some serious heart problems alone carry an increased risk of sudden death, atomoxetine oral solution generally should not be used in pediatric patients with known serious structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or other serious cardiac problems. Consideration should be given to not treating adults with atomoxetine oral solution with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should stop atomoxetine oral solution and undergo a prompt cardiac evaluation. Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems​​​​​​​ Pediatric Patients 6 Years of Age and Older: Sudden death has been reported in association with atomoxetine treatment at the recommended dosage in pediatric patients 6 years of age and older with structural cardiac abnormalities or other serious heart problems. Adults: Sudden deaths, stroke, and myocardial infarction have been reported in atomoxetine-treated adults at the recommended ADHD dosage. Although the role of atomoxetine in these adult cases is also unknown, adults have a greater likelihood than pediatric patients of having serious structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other serious cardiac problems. 5.4 Increases in Blood Pressure and Heart Rate Atomoxetine oral solution is contraindicated in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they had a clinically important increase in blood pressure or heart rate. Atomoxetine oral solution should be used with caution in any condition that may predispose patients to hypotension, or conditions associated with abrupt heart rate or blood pressure changes. Atomoxetine oral solution should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine oral solution dosage increases, and periodically while on therapy to detect possible clinically important increases in heart rate and blood pressure. In the pediatric and adult patients in short-term, placebo-controlled clinical studies of ADHD, there were a greater proportion of patients treated with another atomoxetine product, compared to placebo-treated patients, who had an increase in: diastolic blood pressure (DBP) ≥ 15 mm Hg, systolic blood pressure (SBP) ≥ 20 mm Hg, and heart rate ≥ 20 bpm [see Adverse Reactions (6.1) ] . Increase in Blood Pressure and Heart Rate In placebo-controlled studies of pediatric patients 6 years of age and older with ADHD, tachycardia was identified as an adverse reaction in 0.3% (5/1,597) of patients treated with another atomoxetine product compared with 0% (0/934) of placebo-treated patients. In placebo-controlled adult ADHD studies, tachycardia was identified as an adverse reaction for 1.5% (8/540) of patients treated with another atomoxetine product compared with 0.5% (2/402) of placebotreated patients. Orthostatic hypotension and syncope have been reported in atomoxetine-treated patients. In ADHD studies in pediatric patients 6 years of age and older, 0.2% (12/5,596) of patients treated with another atomoxetine product had orthostatic hypotension and 0.8% (46/5,596) had syncope. In short-term ADHD studies in pediatric patients 6 years of age and older, 1.8% (6/340) of patients treated with another atomoxetine product had orthostatic hypotension compared with 0.5% (1/207) of placebotreated patients. Syncope was not reported during these studies. Increase in Blood Pressure and Heart Rate in CYP2D6 Poor Metabolizers In placebo-controlled studies of pediatric patients 6 years of age and older with ADHD treated with another atomoxetine product, the mean heart rate increase was 9.4 beats/minute in CYP2D6 poor metabolizers and was 5 beats/minute in other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate). In adult clinical trials where CYP2D6 metabolizer status was available, for patients treated with another atomoxetine product the mean heart rate increase in CYP2D6 poor metabolizers was significantly higher than in other CYP2D6 metabolizer types (11 beats/minute versus 7.5 beats/minute, respectively). In adult clinical trials where CYP2D6 metabolizer status was available, for patients treated with another atomoxetine product the mean change from baseline in DBP in CYP2D6 poor metabolizers was higher than in other CYP2D6 metabolizer types (4.2 versus 2.1 mm Hg) as was the mean change from baseline in SBP (CYP2D6 poor metabolizers: 2.8 versus other CYP2D6 metabolizer types: 2.4 mm Hg). 5.5 New Psychotic or Manic Symptoms and Activation of Mania If psychotic or manic symptoms occur, consider discontinuing atomoxetine oral solution. Psychotic symptoms (e.g., hallucinations, delusional thinking), manic symptoms (e.g., mania) in patients without a prior history of psychotic illness or mania can be caused by atomoxetine oral solution at the recommended dosage. 5.6 Screening Patients for Bipolar Disorder Before initiating treatment with atomoxetine oral solution, patients should be adequately screened for risk factors for bipolar disorder such as a personal or family history of mania and depression. Patients with bipolar disorder or risk factors for bipolar disorder may be at increased risk of developing mania or mixed episodes during treatment with atomoxetine oral solution. It may not be possible to determine whether a manic or mixed episode that appears during treatment with atomoxetine oral solution is due to an adverse reaction to atomoxetine oral solution or a patient’s underlying bipolar disorder. 5.7 Aggressive Behavior or Hostility Patients beginning treatment with atomoxetine oral solution should be monitored for the appearance or worsening of aggressive behavior or hostility. There is evidence that atomoxetine oral solution may cause the emergence or worsening of aggressive behavior or hostility. ADHD and other mental illnesses can be associated with irritability, which can make it difficult to determine if atomoxetine oral solution or the underlying psychiatric condition is causing the emergence or worsening of aggressive behavior or hostility in specific patients. If such symptoms occur during treatment, consider a possible causal role of atomoxetine oral solution. 5.8 Hypersensitivity Reactions Atomoxetine oral solution is contraindicated in patients with a known hypersensitivity reaction to atomoxetine oral solution or other components of atomoxetine oral solution. Although uncommon, hypersensitivity reactions, including anaphylaxis, angioneurotic edema, urticaria, and rash, have been reported in atomoxetine-treated patients. 5.9 Effects on Urine Outflow A complaint of urinary retention or urinary hesitancy should be considered potentially related to atomoxetine oral solution. In adult ADHD controlled studies, the incidence of urinary retention (1.7% (9/540)) and urinary hesitation (5.6% (30/540)) were increased among patients treated with another atomoxetine product compared with placebo-treated patients (0% (0/402); 0.5% (2/402), respectively). Two adult patients treated with another atomoxetine product and no placebo-treated patients discontinued from controlled clinical studies because of urinary retention. 5.10 Priapism Prompt medical attention is required in the event of suspected priapism in atomoxetine oral solution-treated patients. Rare postmarketing cases of priapism, defined as painful and nonpainful penile erection lasting more than 4 hours, have been reported for pediatric and adult patients treated with atomoxetine. The erections resolved in cases in which follow-up information was available, some following discontinuation of atomoxetine. 5.11 Effect on Growth in Pediatric Patients Closely monitor growth (e.g., weight, height) in pediatric patients during atomoxetine oral solution treatment. Weight and Height in Long-Term Open-Label Studies in Pediatric Patients Data on the long-term effects of another atomoxetine product on growth in pediatric patients from open-label studies in which weight and height changes were compared to normative pediatric population data are presented below. In general, the weight and height gain of atomoxetine-treated pediatric patients treated with another atomoxetine product lagged behind that predicted by normative population data for about the first 9-12 months of treatment, and subsequently (see Figure 1 below): Weight gain rebounded. At about 3 years of treatment with another atomoxetine product, patients gained a mean of 17.9 kg, which was 0.5 kg more than predicted by their baseline data. Height gain stabilized. At 3 years of treatment with another atomoxetine product, patients gained a mean of 19.4 cm, which was 0.4 cm less than predicted by their baseline data. Figure 1: Mean Weight and Height Percentiles Over Time for Atomoxetine-Treated Pediatric Patients in Comparison to Normative Pediatric Population Values After three years of treatment with another atomoxetine product in the long-term open-label studies, patients who were: Pre-pubertal at the start of treatment (girls ≤8 years old, boys ≤9 years old) gained weight and height; however, the mean weight gain was 2.1 kg less than predicted and the mean height gain was 1.2 cm less than predicted. Pubertal (girls >8 to ≤13 years old, boys >9 to ≤14 years old) or late pubertal (girls >13 years old, boys >14 years old), the mean weight and height gains were close to or exceeded predicted weight and height gains. CYP2D6 poor metabolizers and other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate) treated with another atomoxetine product for at least two years gained weight and height. However, in: CYP2D6 poor metabolizers, the mean weight gain was 2.4 kg less than predicted and the mean height gain was 1.1 cm less than predicted Other CYP2D6 metabolizer types, the mean weight gain was 0.2 kg less than predicted and the mean height gain was 0.4 cm less than predicted. In the long-term open-label studies, the growth pattern was generally similar regardless of pubertal status at the time treatment initiation with another atomoxetine product. Weight and Height in Short-Term, Placebo-Controlled Studies in Pediatric Patients ​​​​​​​In short-term, placebo-controlled studies (up to 9 weeks), patients treated with another atomoxetine product lost an average of 0.4 kg in weight and gained an average of 0.9 cm in height, compared to a gain of 1.5 kg in weight and 1.1 cm in height in the placebo-treated patients. In a fixed-dose controlled trial, 1.3%, 7.1%, 19.3%, and 29.1% of patients in the placebo, 0.5, 1.2, and 1.8 mg/kg/day other atomoxetine product groups, respectively, lost at least 3.5% of their body weight. "Image Description"

6 ADVERSE REACTIONS Most common adverse reactions (≥5% and at least twice the incidence of placebo patients): Pediatric Clinical Studies: Nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence. ( 6.1 ) Adult Clinical Studies: Constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation. ( 6.1 ) Patients should be instructed to use caution when driving a car or operating hazardous machinery (because of somnolence) until they are reasonably certain that their performance is not affected by atomoxetine oral solution ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 1-866-488-0312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of atomoxetine oral solution has been established from adequate and well-controlled studies of atomoxetine capsules (also referred to as another atomoxetine product) in patients 6 years of age and older with ADHD [see Clinical Studies (14) ] . Below is a display of the adverse reactions of [atomoxetine capsules in these adequate and well-controlled studies. Atomoxetine capsules were administered to 5,382 pediatric patients 6 years of age and older in clinical ADHD studies (Studies 1, 2, 3, 4, and 5) [see Clinical Studies (14.1) ] and 1,007 adults in clinical ADHD studies (Studies 6 and 7) [see Clinical Studies (14.2) ] . In the ADHD clinical trials, 2,529 pediatric patients were treated for over 6 months, which included 1,625 pediatric patients who were treated for longer than 1 year. Adverse Reactions in the Clinical Trials of Pediatric Patients 6 Years of Age and Older with ADHD Discontinuation of Treatment Due to Adverse Reactions in the Clinical Studies of Pediatric Patients 6 Years of Age and Older: In the acute placebo-controlled studies of pediatric patients 6 years of age and older with ADHD, 3% (48/1,613) of atomoxetine capsules-treated pediatric patients and 1.4% (13/945) of placebo-treated pediatric patients discontinued due to an adverse reaction. Among atomoxetine capsules-treated patients, irritability (0.3%, N=5); somnolence (0.3%, N=5); aggression (0.2%, N=4); nausea (0.2%, N=4); vomiting (0.2%, N=4); abdominal pain (0.2%, N=4); constipation (0.1%, N=2); fatigue (0.1%, N=2); feeling abnormal (0.1%, N=2); and headache (0.1%, N=2) were the reasons for discontinuation reported by more than one patient. For all studies, (including open-label and long-term studies), 6% of atomoxetine capsules-treated pediatric patients who were other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate) and 11% of those who were CYP2D6 poor metabolizers discontinued due to an adverse reaction. Common Adverse Reactions in the Clinical Studies of Pediatric Patients 6 Years of Age and Older: Common adverse reactions (incidence of 2% or greater in atomoxetine capsules-treated patients and with a higher incidence in atomoxetine capsules-treated patients compared to placebo-treated patients) in pediatric patients 6 years of age and older with ADHD are listed in Table 3. The most commonly observed adverse reactions in atomoxetine capsules-treated patients (incidence of ≥5% and ≥twice the incidence in placebo-treated patients), for either twice daily or once daily dosing were: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence (see Tables 3 and 4). Table 3: Common Adverse Reactions a in Acute Studies (up to 18 weeks) in Pediatric Patients 6 Years and Older with ADHD Atomoxetine Capsules (N=1,597) Placebo (N=934) Headache 19% 15% Abdominal pain b 18% 10% Decreased appetite 16% 4% Somnolence c 11% 4% Vomiting 11% 6% Nausea 10% 5% Fatigue 8% 3% Irritability 6% 3% Dizziness 5% 2% Decrease weight 3% 0% Anorexia 3% 1% Rash 2% 1% a Adverse reactions reported by at least 2% of atomoxetine capsules-treated patients and greater than placebo-treated patients. b Abdominal pain includes the terms: upper abdominal pain and epigastric discomfort. c Somnolence includes the term sedation. Adverse reaction in the atomoxetine capsules-treated patients who received twice daily, and once daily dosing are shown in Table 4 (adverse reactions based on statistically significant Breslow-Day tests). Table 4: Common Adverse Reactions in Acute studies (up to 18 weeks) in Pediatric Patients 6 Years and Older with ADHD​​​​​​​​​​​​​​ ADHD Studies with Twice Daily Dosing ADHD Studies with Once Daily Dosing Atomoxetine Capsules (N=715) Placebo (N=434) Atomoxetine Capsules (N=882) Placebo (N=500) Abdominal pain a 17% 13% 18% 7% Vomiting 11% 8% 11% 4% Nausea 7% 6% 13% 4% Fatigue 6% 4% 9% 2% Mood swings b 2% 0% 1% 1% Constipation c 2% 1% 1% 0% a Abdominal pain includes the terms: upper abdominal pain upper, epigastric discomfort. b Mood swings didn’t meet the statistical significance on Breslow-Day test at 0.05 level, but p-value was <0.1 (trend). c Constipation didn’t meet the statistical significance on Breslow-Day test but is included in the table because of pharmacologic plausibility. Common Adverse Reactions by CYP2D6 Metabolizer Status in the Clinical Studies of Pediatric Patients 6 Years of Age and Older: Table 5 displays adverse reactions occurred in at least 2% of atomoxetine capsules-treated pediatric patients who were CYP2D6 poor metabolizers and were statistically significantly more frequent in CYP2D6 poor metabolizers compared with other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate). Table 5: Common Adverse Reactions a in Acute Studies (up to 18 weeks) in Atomoxetine Capsules-Treated Pediatric Patients 6 Years and Older with ADHD by CYP2D6 Metabolizer Types​​​​​​​ Atomoxetine Capsules CYP2D6 Poor Metabolizers (N=5,019) Atomoxetine Capsules Other CYP2D6 Metabolizer Types (N=355) Insomnia 11% 6% Decreased weight 7% 4% Constipation 7% 4% Depression b 7% 4% Tremor 5% 1% Excoriation 4% 2% Sedation 4% 2% Middle insomnia 3% 1% Conjunctivitis 3% 1% Syncope 3% 1% Early morning awakening 2% 1% Mydriasis 2% 1% a Adverse reactions that occurred in at least 2% of atomoxetine capsules-treated pediatric patients who were CYP2D6 poor metabolizers and were statistically significantly more frequent in poor metabolizers compared with other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate). b Depression included the following terms: major depression, depressive symptoms, depressed mood, dysphoria. Less Common Adverse Reactions in the Clinical Studies of Pediatric Patients 6 Years of Age and Older: The following reactions did not meet this criterion but were reported by more atomoxetine capsules-treated patients than placebo-treated patients and are possibly related to atomoxetine capsules treatment: blood pressure increased, early morning awakening (terminal insomnia), flushing, mydriasis, sinus tachycardia, asthenia, palpitations, mood swings, constipation, and dyspepsia. The following reactions were reported by at least 2% of patients treated with atomoxetine, and equal to or less than placebo: pharyngolaryngeal pain, insomnia (insomnia includes the terms, insomnia, initial insomnia, middle insomnia). The following reaction did not meet this criterion but shows a statistically significant dose relationship: pruritus. Seizures in the Clinical Studies of Pediatric Patients 6 Years of Age and Older: Atomoxetine has not been systematically evaluated in pediatric patients with seizure disorder as these patients were excluded from clinical studies in the atomoxetine capsules studies. In the clinical development program, seizures were reported in 0.2% (12/5,073) of atomoxetine capsules-treated pediatric patients whose average age was 10 years old (range 6 to 16 years of age). In these clinical trials, for atomoxetine capsules-treated pediatric patients the seizure incidence among CYP2D6 poor metabolizers was 0.3% (1/293) compared to 0.2% (11/4,741) for other CYP2D6 metabolizer types. Heart Rate and Blood Pressure Increases in the Clinical Studies of Pediatric Patients 6 Years of Age and Older: Additional data from ADHD clinical trials (controlled and uncontrolled) has shown that approximately 5 to 10% of pediatric patients treated with atomoxetine capsules experienced potentially clinically important changes in heart rate (≥20 beats per minute) or blood pressure (≥15 to 20 mm Hg) [see Contraindications (4) and Warnings and Precautions (5.4) ] . Adverse Reactions in the Clinical Studies of Adults with ADHD Discontinuation of Treatment Due to Adverse Reactions in the Clinical Studies of Adults: In the acute adult placebo-controlled trials, 11% (61/541) atomoxetine capsules-treated pediatric patients and 3% (12/405) of placebo-treated patients discontinued for adverse reactions. Among atomoxetine capsules-treated patients, insomnia (0.9%, N=5); nausea (0.9%, N=5); chest pain (0.6%, N=3); fatigue (0.6%, N=3); anxiety (0.4%, N=2); erectile dysfunction (0.4%, N=2); mood swings (0.4%, N=2); nervousness (0.4%, N=2); palpitations (0.4%, N=2); and urinary retention (0.4%, N=2) were the reasons for discontinuation reported by more than one patient. Common Adverse Reactions in the Clinical Studies of Adults: Commonly observed adverse reactions associated with the use of atomoxetine capsules (incidence of 2% or greater) and not observed at an equivalent incidence among placebo-treated patients (atomoxetine capsules incidence greater than placebo) are listed in Table 6. The most commonly observed adverse reactions in patients treated with atomoxetine capsules (incidence of 5% or greater and at least twice the incidence in placebo patients) were: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation ( see Table 6). Table 6: Common Adverse Reactions a Associated in Acute Studies (up to 25 weeks) of Adult Patients with ADHD​​​​​​​ Atomoxetine Capsules (N=1697) Placebo (N=1560) Nausea 26% 6% Dry mouth 20% 5% Decreased appetite 16% 3% Insomnia d 15% 8% Fatigue 10% 6% Erectile dysfunction f 8% 1% Constipation 8% 3% Dizziness 8% 3% Somnolence c 8% 5% Abdominal pain b 7% 4% Urinary hesitation e 6% 1% Irritability 5% 3% Ejaculation delayedf and/or ejaculation disorder f 4% 1% Hyperhidrosis 4% 1% Dyspepsia 4% 2% Vomiting 4% 2% Abnormal dreams 4% 3% Chills 3% 0% Paraesthesia 3% 0% Hot flush 3% 0% Palpitations 3% 1% Libido decreased 3% 1% Sleep disorder 3% 1% Dysmenorrhea g 3% 2% Dysuria 2% 0% Thirst 2% 1% Weight decreased 2% 1% Feeling jittery 2% 1% a Reactions reported by at least 2% of patients treated with atomoxetine capsules, and greater than placebo. The following reactions did not meet this criterion but were reported by more atomoxetine-treated patients than placebo-treated patients and are possibly related to atomoxetine treatment: peripheral coldness, tachycardia, prostatitis, testicular pain, orgasm abnormal, flatulence, asthenia, feeling cold, muscle spasm, dysgeusia, agitation, restlessness, micturition urgency, pollakiuria, pruritus, urticaria, flushing, tremor, menstruation irregular, rash, and urinary retention. b Abdominal pain includes the terms: abdominal pain upper, abdominal pain, stomach discomfort, abdominal discomfort, epigastric discomfort. c Somnolence includes the term sedation. d Insomnia includes the terms: insomnia, initial insomnia, middle insomnia, and terminal insomnia. e Urinary hesitation includes the terms: urinary hesitation, urine flow decreased. f Based on total number of males (atomoxetine capsules, N=943; placebo, N=869). g Based on total number of females (atomoxetine capsules, N=754; placebo, N=691). Common Adverse Reactions by CYP2D6 Metabolizer Status in the Clinical Studies of Adults: Table 7 displays adverse reactions that occurred in at least 2% of atomoxetine capsules-treated adult patients who were CYP2D6 poor metabolizers and were statistically significantly more frequent compared to other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate). Table 7: Common Adverse Reactions a in Acute Studies (up to 18 weeks) in Atomoxetine Capsules-Treated Adults with ADHD by CYP2D6 Metabolizer Types​​​​​​​ Atomoxetine Capsules CYP2D6 Poor Metabolizers (N=203) Atomoxetine Capsules Other CYP2D6 Metabolizer Types ​​​​​​​(N=3,599) Dry mouth 35% 17% Decreased appetite 23% 15% Erectile dysfunction 21% 9% Insomnia 19% 11% Hyperhidrosis 15% 7% Constipation 11% 7% Sleep disorder 7% 3% Urinary retention 6% 1% Ejaculation disorder 6% 2% Tremor 5% 1% Feeling jittery 5% 2% Middle insomnia 5% 3% Blurred vision 4% 1% Terminal insomnia 3% 1% Peripheral coldness 3% 1% a Adverse reactions that occurred in at least 2% of atomoxetine capsules-treated pediatric patients who were CYP2D6 poor metabolizers and were statistically significantly more frequent in CYP2D6 poor metabolizers compared with other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate). Less Common Adverse Reactions in the Clinical Studies of Adults:​​​​​​​​​​​​​​ The following reactions did not meet this criterion but were reported by more atomoxetine capsules-treated patients than placebo treated patients and are possibly related to atomoxetine treatment: peripheral coldness, tachycardia, prostatitis, testicular pain, orgasm abnormal, flatulence, asthenia, feeling cold, muscle spasm, dysgeusia, agitation, restlessness, micturition urgency, pollakiuria, pruritus, urticaria, flushing, tremor, menstruation irregular, rash, and urinary retention. Seizures in the Clinical Studies of Adults:​​​​​​​​​​​​​​ Atomoxetine has not been systematically evaluated in adult patients with a seizure disorder as these patients were excluded from clinical studies during the product’s premarket testing. In the clinical development program, seizures were reported on 0.1% (1/748) of adult patients treated with atomoxetine capsules. In these clinical trials, no CYP2D6 poor metabolizers (0/43) reported seizures compared to 0.1% (1/705) for other CYP2D6 metabolizer types. Heart Rate and Blood Pressure Increases in the Clinical Studies of Adults:​​​​​​​​​​​​​​ Table 8 displays the proportion of atomoxetine capsules-treated and placebo-treated patients who had an increase in diastolic blood pressure (DBP) ≥15 mm Hg, systolic blood pressure (SBP) ≥20 mm Hg, or heart rate ≥ 20 bpm in short-term, placebo-controlled clinical studies of in pediatric and adult patients with ADHD [see Warnings and Precautions (5.4) ] . Table 8: Proportion of ADHD Patients With an Increase ≥15 mm Hg in DBP, ≥20 mm Hg in SBP, or ≥20 bpm in Heart Rate a ​​​​​​​​​​​​​​ Pediatric Acute ADHD Studies Adult Acute ADHD Studies Maximum b Endpoint Maximum b Endpoint Atomoxetine Capsules Placebo Atomoxetine Capsules Placebo Atomoxetine Capsules Placebo Atomoxetine Capsules Placebo DBP (≥15 mm Hg) 22% 14% 9% 5% 13% 9% 5% 4% SBP (≥20 mm Hg) 13% 9% 5% 3% 12% 8% 4% 3% HR (≥20 bpm) 23% 12% 12% 4% 22% 8% 10% 2% a Abbreviations: bpm=beats per minute; DBP=diastolic blood pressure; HR=heart rate; mm Hg=millimeters mercury; SBP=systolic blood pressure. b Proportion of patients meeting threshold at any one time during the clinical studies. ​​​​​​​Additional data from ADHD clinical trials (controlled and uncontrolled) showed that approximately 5 to 10% of adult patients treated with atomoxetine capsules had potentially clinically important changes in heart rate (≥20 beats per minute) or blood pressure (≥15 to 20 mm Hg) [see Contraindications (4) and Warnings and Precautions (5.4) ] . Male and Female Sexual Dysfunction in the Clinical Studies of Adults: Atomoxetine capsules impaired sexual function in some patients. Estimates of the incidence of untoward sexual experience and performance in these studies are likely to underestimate their actual incidence because patients and health care providers may be reluctant to discuss them. Sexual adverse reactions reported by at least 2% of atomoxetine capsules-treated adult patients in the placebo-controlled studies of adults with ADHD (i.e., erectile dysfunction, dysmenorrhea, and ejaculation delayed and/or ejaculation disorder). There are no adequate and well-controlled studies examining sexual dysfunction with atomoxetine treatment. While it is difficult to know the precise risk of sexual dysfunction associated with the use of atomoxetine, health care providers should routinely inquire about sexual dysfunction. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of atomoxetine. Unless otherwise specified, these adverse reactions have occurred in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular system: QT prolongation, syncope. Peripheral vascular effects: Raynaud’s phenomenon. General disorders and administration site conditions: Lethargy Musculoskeletal system: Rhabdomyolysis. Nervous system disorders: Hypoaesthesia; paraesthesia in pediatric patients; sensory disturbances; tics. Psychiatric disorders: Depression and depressed mood; anxiety, libido changes. Seizures: Seizures have been reported and included patients with pre-existing seizure disorders, those with identified risk factors for seizures, and patients with neither a history of nor identified risk factors for seizures. The exact relationship between atomoxetine and seizures is difficult to evaluate due to uncertainty about the background risk of seizures in ADHD patients. Skin and subcutaneous tissue disorders: Alopecia, hyperhidrosis. Urogenital system: Male pelvic pain; urinary hesitation in pediatric patients; urinary retention in pediatric patients.

<table cellspacing="0" width="70%" styleCode="Noautorules"><tbody><tr><td styleCode="Botrule Lrule Rrule Toprule"> </td><td align="center" styleCode="Botrule Rrule Toprule"><paragraph><content styleCode="bold">Atomoxetine Capsules (N=1,597) </content></paragraph></td><td align="center" styleCode="Botrule Rrule Toprule"><paragraph><content styleCode="bold">Placebo (N=934) </content></paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Headache</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>19%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>15%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Abdominal pain ^b</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>18%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>10%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Decreased appetite</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>16%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Somnolence ^c</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>11%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>11%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>6%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>10%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>5%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Fatigue</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>8%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Irritability</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>6%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Dizziness</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Decrease weight</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>0%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Anorexia</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Rash</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td colspan="3"><paragraph>^aAdverse reactions reported by at least 2% of atomoxetine capsules-treated patients and greater than placebo-treated patients. ^bAbdominal pain includes the terms: upper abdominal pain and epigastric discomfort. ^cSomnolence includes the term sedation. </paragraph></td></tr></tbody></table>

<table cellspacing="0" width="70%" styleCode="Noautorules"><tbody><tr><td rowspan="2" styleCode="Botrule Lrule Rrule Toprule"> </td><td colspan="2" align="center" styleCode="Botrule Rrule Toprule"><paragraph><content styleCode="bold">ADHD Studies with Twice Daily Dosing</content></paragraph></td><td colspan="2" align="center" styleCode="Botrule Rrule Toprule"><paragraph><content styleCode="bold">ADHD Studies with Once Daily Dosing</content></paragraph></td></tr><tr><td align="center" styleCode="Botrule Rrule"><paragraph><content styleCode="bold">Atomoxetine Capsules</content> <content styleCode="bold">(N=715)</content></paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph><content styleCode="bold">Placebo</content> <content styleCode="bold">(N=434)</content></paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph><content styleCode="bold">Atomoxetine Capsules</content> <content styleCode="bold">(N=882)</content></paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph><content styleCode="bold">Placebo</content> <content styleCode="bold">(N=500)</content></paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Abdominal pain ^a</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>17%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>13%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>18%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>7%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>11%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>8%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>11%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>7%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>6%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>13%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Fatigue</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>6%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>9%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Mood swings ^b</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>0%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Constipation ^c</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>0%</paragraph></td></tr><tr><td colspan="5"><paragraph>^aAbdominal pain includes the terms: upper abdominal pain upper, epigastric discomfort. ^bMood swings didn&#x2019;t meet the statistical significance on Breslow-Day test at 0.05 level, but p-value was &lt;0.1 (trend). ^cConstipation didn&#x2019;t meet the statistical significance on Breslow-Day test but is included in the table because of pharmacologic plausibility. </paragraph></td></tr></tbody></table>

<table cellspacing="0" width="70%" styleCode="Noautorules"><tbody><tr><td styleCode="Botrule Lrule Rrule Toprule"> </td><td align="center" styleCode="Botrule Rrule Toprule"><paragraph><content styleCode="bold">Atomoxetine Capsules CYP2D6 Poor Metabolizers (N=5,019) </content></paragraph></td><td align="center" styleCode="Botrule Rrule Toprule" valign="top"><paragraph><content styleCode="bold">Atomoxetine Capsules Other CYP2D6 Metabolizer Types (N=355) </content></paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Insomnia</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>11%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>6%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Decreased weight</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>7%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Constipation</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>7%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Depression ^b</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>7%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Tremor</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Excoriation</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Sedation</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>4%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Middle insomnia</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Conjunctivitis</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Syncope</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Early morning awakening</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Lrule Rrule"><paragraph>Mydriasis</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule"><paragraph>1%</paragraph></td></tr><tr><td colspan="3"><paragraph>^aAdverse reactions that occurred in at least 2% of atomoxetine capsules-treated pediatric patients who were CYP2D6 poor metabolizers and were statistically significantly more frequent in poor metabolizers compared with other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate). ^bDepression included the following terms: major depression, depressive symptoms, depressed mood, dysphoria. </paragraph></td></tr></tbody></table>